公开(公告)号：WO2009089521A2

公开(公告)日：2009-07-16

申请号：PCT/US2009/030719

申请日：2009-01-12

Applicant: NUVERA BIOSCIENCES, INC. ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  SYMMANS, W., Fraser ,  HATZIS, Christos ,  PUSZTAI, Lajos

Inventor： SYMMANS, W., Fraser ,  HATZIS, Christos ,  PUSZTAI, Lajos

IPC: G01N33/574

CPC classification number: G01N33/57484 ,  G01N2800/52 ,  G01N2800/60 ,  G06F19/20 ,  G06F19/28

Abstract: Embodiments of the invention include methods of evaluating a patient and determining the likelihood of a treatment outcome to one or four categories of residual cancer burden classification.

Abstract translation: 本发明的实施方案包括评估患者并确定治疗结果对一种或四类残留癌症负担分类的可能性的方法。

公开(公告)号：WO2008073629A9

公开(公告)日：2008-09-25

申请号：PCT/US2007083651

申请日：2007-11-05

Applicant: UNIV TEXAS ,  NUVERA BIOSCIENCES INC ,  HATZIS CHRISTOS ,  SYMMANS FRASER W ,  PUSZTAI LAJOS

Inventor： HATZIS CHRISTOS ,  SYMMANS FRASER W ,  PUSZTAI LAJOS

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136

Abstract: The present invention provides the identification of genes that are expressed in tumors to indicate responsiveness or resistance to an agent or class of agents. More particularly, these genes show expression associated with responsiveness to one agent or class of agents is inversely related to expression in association with another class of agents. One or more of theses genes of the present invention can be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by the responsive agent as well as to identify tumors that should avoid treatment by the resistant agent.

公开(公告)号：WO2011130495A1

公开(公告)日：2011-10-20

申请号：PCT/US2011/032462

申请日：2011-04-14

Applicant: NUVERA BIOSCIENCES, INC. ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  HATZIS, Christos ,  SYMMANS, W., Fraser

Inventor： HATZIS, Christos ,  SYMMANS, W., Fraser

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q1/68 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57492 ,  G01N2333/91205 ,  G06F19/18 ,  G06F19/20 ,  G06F19/24 ,  G06F19/34 ,  H04L67/00

Abstract: A method of evaluating a cancer patient comprising evaluating gene expression levels in a patient sample, calculating a predictor score using the gene expression levels, and assessing the likelihood of a therapeutic outcome using the predictor score is disclosed.

Abstract translation: 一种评估癌症患者的方法，包括评估患者样品中的基因表达水平，使用基因表达水平计算预测因子评分，以及使用预测因子评分评估治疗结果的可能性。

公开(公告)号：WO2010127338A1

公开(公告)日：2010-11-04

申请号：PCT/US2010/033359

申请日：2010-05-03

Applicant: NUVERA BIOSCIENCES, INC. ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  SYMMANS, W., Fraser ,  HATZIS, Christos ,  PUSZTAI, Lajos

Inventor： SYMMANS, W., Fraser ,  HATZIS, Christos ,  PUSZTAI, Lajos

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  G06F19/20

Abstract: The present invention provides the identification and combination of genes that are expressed in tumors that are responsive to a given therapeutic agent and whose combined expression can be used as an index that correlates with responsiveness to that therapeutic agent. One or more of the genes of the present invention may be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by that agent or class of agents such as hormonal or endocrine therapy or chemotherapy.

Abstract translation: 本发明提供了在对给定治疗剂有反应的肿瘤中表达的基因的鉴定和组合，并且其组合表达可用作与对该治疗剂的反应性相关的指标。 本发明的一个或多个基因可用作标志物（或替代标记物），以鉴定可能由该试剂或类别的试剂例如激素或内分泌治疗或化学疗法成功治疗的肿瘤。

公开(公告)号：WO2009089521A3

公开(公告)日：2009-10-08

申请号：PCT/US2009030719

申请日：2009-01-12

Applicant: NUVERA BIOSCIENCES INC ,  UNIV TEXAS ,  SYMMANS W FRASER ,  HATZIS CHRISTOS ,  PUSZTAI LAJOS

Inventor： SYMMANS W FRASER ,  HATZIS CHRISTOS ,  PUSZTAI LAJOS

IPC: G01N33/574

CPC classification number: G01N33/57484 ,  G01N2800/52 ,  G01N2800/60 ,  G06F19/20 ,  G06F19/28

Abstract: Embodiments of the invention include methods of evaluating a patient and determining the likelihood of a treatment outcome to one or four categories of residual cancer burden classification.

Abstract translation: 本发明的实施例包括评估患者和确定对一类或四类残余癌症负荷分类的治疗结果的可能性的方法。

公开(公告)号：WO2008073629A3

公开(公告)日：2008-06-19

申请号：PCT/US2007/083651

申请日：2007-11-05

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  NUVERA BIOSCIENCES, INC. ,  HATZIS, Christos ,  SYMMANS, Fraser, W. ,  PUSZTAI, Lajos

Inventor： HATZIS, Christos ,  SYMMANS, Fraser, W. ,  PUSZTAI, Lajos

IPC: C12Q1/68 ,  G01N33/53

Abstract: The present invention provides the identification of genes that are expressed in tumors to indicate responsiveness or resistance to an agent or class of agents. More particularly, these genes show expression associated with responsiveness to one agent or class of agents is inversely related to expression in association with another class of agents. One or more of theses genes of the present invention can be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by the responsive agent as well as to identify tumors that should avoid treatment by the resistant agent.

公开(公告)号：WO2008073629A2

公开(公告)日：2008-06-19

申请号：PCT/US2007083651

申请日：2007-11-05

Applicant: UNIV TEXAS ,  NUVERA BIOSCIENCES INC ,  HATZIS CHRISTOS ,  SYMMANS FRASER W ,  PUSZTAI LAJOS

Inventor： HATZIS CHRISTOS ,  SYMMANS FRASER W ,  PUSZTAI LAJOS

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136

Abstract: The present invention provides the identification of genes that are expressed in tumors to indicate responsiveness or resistance to an agent or class of agents. More particularly, these genes show expression associated with responsiveness to one agent or class of agents is inversely related to expression in association with another class of agents. One or more of theses genes of the present invention can be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by the responsive agent as well as to identify tumors that should avoid treatment by the resistant agent.

Abstract translation: 本发明提供了在肿瘤中表达的基因的鉴定以指示对药剂或药剂类别的反应性或抗性。 更特别地，这些基因显示与对一种试剂或一类试剂的响应性相关的表达与另一类试剂的表达负相关。 本发明的一个或多个基因可用作标志物（或替代标志物）来鉴定可能成功通过响应剂处理的肿瘤以及鉴定应避免由抗性药剂治疗的肿瘤。